# Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments

> **NCT05769868** · PHASE3 · RECRUITING · sponsor: **Consorcio Centro de Investigación Biomédica en Red (CIBER)** · enrollment: 1000 (estimated)

## Conditions studied

- Cirrhosis
- Diabetes Mellitus
- Oncologic Disorders

## Interventions

- **DRUG:** Esmolol Injection [Brevibloc]

## Key facts

- **NCT ID:** NCT05769868
- **Lead sponsor:** Consorcio Centro de Investigación Biomédica en Red (CIBER)
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-18
- **Primary completion:** 2027-03
- **Final completion:** 2027-09
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05769868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05769868, "Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05769868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*